Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Tools Permit Delicate Manipulation of the Stem Cell Genome

By LabMedica International staff writers
Posted on 09 Aug 2011
Researchers have compared the effectiveness of two methods for modifying the genomes of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.

Investigators at the Whitehead Institute (Cambridge, MA, USA) initially employed zinc finger nucleases (ZFNs) to modify a single base pair in the iPS genome. More...
Zinc-finger nucleases (ZFNs) are artificial restriction enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. Zinc finger domains can be engineered to target desired DNA sequences, and this enables zinc-finger nucleases to target unique sequences within complex genomes. By taking advantage of endogenous DNA repair machinery, these reagents can be used to precisely alter the genomes of higher organisms.

The modification, as described in the July 14, 2011, online edition of the journal Cell, was either the insertion or deletion of the mutation that causes early-onset Parkinson’s disease (PD). This technology allowed the researchers to study the same cell line in both a normal and diseased state.

In a parallel study published in the July 7, 2011, online edition of the journal Nature Biotechnology the investigators used an entirely different technique to modify the genome. Here they used transcription activator like effector nucleases (TALENs) instead of ZFNs. They reported that TALENs - employing the specific architectures described in their study - mediated site-specific genome modification in human pluripotent cells with similar efficiency and precision, as did ZFNs.

Both the ZFNs and the TALENs used in these studies were produced by Sangamo BioSciences (Richmond, CA, USA).

“It is very important that the cells be genetically identical and have the same history, then make or remove only that mutation,” said senior author Dr. Rudolf Jaenisch, professor of biology at the Whitehead Institute. “If you use control cells from one person and a diseased cell from another person, it is like comparing apples and oranges. This is very relevant for diseases like Parkinson’s, which likely will display only subtle phenotypes in the Petri dish. ”

Related Links:
Whitehead Institute
Sangamo BioSciences



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.